These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24100492)

  • 1. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.
    Chopra T; Marchaim D; Awali RA; Krishna A; Johnson P; Tansek R; Chaudary K; Lephart P; Slim J; Hothi J; Ahmed H; Pogue JM; Zhao JJ; Kaye KS
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6270-5. PubMed ID: 24100492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.
    Smolyakov R; Borer A; Riesenberg K; Schlaeffer F; Alkan M; Porath A; Rimar D; Almog Y; Gilad J
    J Hosp Infect; 2003 May; 54(1):32-8. PubMed ID: 12767844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in
    Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT
    J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
    Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
    Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
    Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
    Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.
    Tal-Jasper R; Katz DE; Amrami N; Ravid D; Avivi D; Zaidenstein R; Lazarovitch T; Dadon M; Kaye KS; Marchaim D
    Antimicrob Agents Chemother; 2016 May; 60(5):3127-31. PubMed ID: 26883694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
    Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
    Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
    Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
    J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
    Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Lin HS; Lee MH; Cheng CW; Hsu PC; Leu HS; Huang CT; Ye JJ
    Infect Dis (Lond); 2015 Jun; 47(6):370-8. PubMed ID: 25746600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.
    Yu K; Zeng W; Xu Y; Liao W; Xu W; Zhou T; Cao J; Chen L
    Antimicrob Resist Infect Control; 2021 Jan; 10(1):16. PubMed ID: 33461617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of multidrug-resistant
    Sun L; Wang X; Li Z
    Br J Neurosurg; 2018 Dec; 32(6):642-645. PubMed ID: 28431478
    [No Abstract]   [Full Text] [Related]  

  • 16. [Risk factors and resistance patterns of invasive
    Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
    Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system.
    Reddy T; Chopra T; Marchaim D; Pogue JM; Alangaden G; Salimnia H; Boikov D; Navon-Venezia S; Akins R; Selman P; Dhar S; Kaye KS
    Antimicrob Agents Chemother; 2010 May; 54(5):2235-8. PubMed ID: 20211887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
    Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.